PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35501518-0 2022 The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Iodine-131 96-107 telomerase reverse transcriptase Homo sapiens 35-39 24476079-11 2014 Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). Iodine-131 75-86 telomerase reverse transcriptase Homo sapiens 28-32 35311230-11 2022 However, tumors with more than 30% hobnail areas frequently present TERT promoter mutations, advanced disease stage, and structural persistence after radioiodine ablation. Iodine-131 150-161 telomerase reverse transcriptase Homo sapiens 68-72 31375570-0 2020 The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. Iodine-131 85-96 telomerase reverse transcriptase Homo sapiens 35-39 27493271-0 2017 TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. Iodine-131 32-43 telomerase reverse transcriptase Homo sapiens 0-4 27493271-9 2017 TERT mutation closely correlated with a poor response to radioiodine therapy (P < 0.001), and all 15 patients were classified as refractory to radioiodine therapy, with a positive predictive value of 100% at the endpoint of follow-up. Iodine-131 57-68 telomerase reverse transcriptase Homo sapiens 0-4 27493271-10 2017 TERT mutation was associated with older mean age at diagnosis (P < 0.001), larger mean tumor diameter (P = 0.013), and greater likelihood of both BRAF mutation coexistence (P = 0.044) and radioiodine-refractory character (P < 0.001). Iodine-131 191-202 telomerase reverse transcriptase Homo sapiens 0-4 27493271-11 2017 In the 36 cases whose imaging results underwent semiquantitative analysis, TERT mutation significantly correlated with non-radioiodine avidity, with a much lower mean tumor-to-background ratio (obtained from postradioiodine whole-body scanning) than in TERT wild-type cases (P < 0.001). Iodine-131 123-134 telomerase reverse transcriptase Homo sapiens 75-79 27493271-12 2017 In addition, patients with distant metastatic DTC with TERT mutation were more likely to lose radioiodine avidity at the initial radioiodine therapy than were those with only BRAF mutation (8/8 vs. 5/11; Fisher exact test, P = 0.018). Iodine-131 94-105 telomerase reverse transcriptase Homo sapiens 55-59 27493271-12 2017 In addition, patients with distant metastatic DTC with TERT mutation were more likely to lose radioiodine avidity at the initial radioiodine therapy than were those with only BRAF mutation (8/8 vs. 5/11; Fisher exact test, P = 0.018). Iodine-131 129-140 telomerase reverse transcriptase Homo sapiens 55-59 27493271-13 2017 CONCLUSION: TERT mutation closely associates with non-radioiodine avidity in distant metastatic DTC, and when compared with BRAF mutation, TERT mutation manifested a greater negative influence on radioiodine uptake. Iodine-131 54-65 telomerase reverse transcriptase Homo sapiens 12-16 27493271-13 2017 CONCLUSION: TERT mutation closely associates with non-radioiodine avidity in distant metastatic DTC, and when compared with BRAF mutation, TERT mutation manifested a greater negative influence on radioiodine uptake. Iodine-131 196-207 telomerase reverse transcriptase Homo sapiens 139-143 27493271-14 2017 TERT mutation could also be used as an early predictor of radioiodine-refractory cases. Iodine-131 58-69 telomerase reverse transcriptase Homo sapiens 0-4 26857243-8 2016 In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025). Iodine-131 141-152 telomerase reverse transcriptase Homo sapiens 80-84 25410753-0 2015 Glial fibrillary acidic protein promoters direct adenovirus early 1A gene and human telomerase reverse transcriptase promoters direct sodium iodide symporter expression for malignant glioma radioiodine therapy. Iodine-131 190-201 telomerase reverse transcriptase Homo sapiens 84-116 31412230-12 2019 Tumors carrying RAS, TERT or a combination of these mutations were radioiodine-avid, with predictable tumor response and reduction in serum thyroglobulin levels. Iodine-131 67-78 telomerase reverse transcriptase Homo sapiens 21-25 31412230-13 2019 One patient with radioiodine-refractory disease harbored BRAF and TERT mutations. Iodine-131 17-28 telomerase reverse transcriptase Homo sapiens 66-70 31026111-0 2019 TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131 i uptake in metastases. Iodine-131 95-100 telomerase reverse transcriptase Homo sapiens 0-4 31026111-12 2019 Multivariate analyses demonstrated that the TERT mutation was associated with decreased 131 I uptake and the RAIR categories of absent or weaker 131 I uptake. Iodine-131 88-93 telomerase reverse transcriptase Homo sapiens 44-48 31026111-12 2019 Multivariate analyses demonstrated that the TERT mutation was associated with decreased 131 I uptake and the RAIR categories of absent or weaker 131 I uptake. Iodine-131 145-150 telomerase reverse transcriptase Homo sapiens 44-48 29413688-14 2018 TERT promoter mutations at positions -124 (C228T) and -146 (C250T) were present in 38.1% of analysed patients and significantly associated with radioiodine resistance but not with overall survival. Iodine-131 144-155 telomerase reverse transcriptase Homo sapiens 0-4 22412937-3 2012 Ad5/3-hTERT-hNIS expresses hNIS for imaging of transgene expression and for treatment of infected tumors by radioiodine. Iodine-131 108-119 telomerase reverse transcriptase Homo sapiens 6-11 22412937-5 2012 Survival of mice treated with intravenous Ad5/3-hTERT-hNIS significantly prolonged survival over mock or radioiodine only but the combination of virus with radioiodine was not more effective than virus alone. Iodine-131 105-116 telomerase reverse transcriptase Homo sapiens 48-53 21797672-0 2011 Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells. Iodine-131 140-151 telomerase reverse transcriptase Homo sapiens 85-117 21797672-4 2011 METHODS: We used hTERT promoter-modulated expression of the hNIS and human thyroperoxidase (hTPO) genes in an experimental model of radioiodine-based treatment of malignant glioma. Iodine-131 132-143 telomerase reverse transcriptase Homo sapiens 17-22 21801606-0 2011 Telomerase reverse transcriptase promoter-driven expression of iodine pump genes for targeted radioiodine therapy of malignant glioma cells. Iodine-131 94-105 telomerase reverse transcriptase Homo sapiens 0-32 21801606-11 2011 These results demonstrated that radioiodine therapy was effective in treating malignant glioma cell lines following induction of tumor-specific iodide intake by the hTERT promoter-directed hNIS expression in vitro. Iodine-131 32-43 telomerase reverse transcriptase Homo sapiens 165-170